NCT00104130终止2 期
A Phase 2 Study of KOS-862 Administered Intravenously Weekly for 3 Weeks Every 4 Weeks, in Patients With Hormone Resistant Prostate Cancer Who Have Progressed Following Initial Therapy for Metastatic Disease
Bristol-Myers Squibb18 个研究点 分布在 1 个国家目标入组 53 人开始时间: 2004年12月最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 53
- 试验地点
- 18
- 主要终点
- prostate cancer
研究概览
简要总结
The purpose of this trial is to study KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen.
详细描述
This study is a Phase 2, single arm study of KOS-862 in men with metastatic prostate cancer who have failed a docetaxel-containing regimen. PSA response is the primary end-point and objective responses will be checked as available.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •At least 18 years of age.
- •Metastatic disease.
- •One previous treatment including docetaxel (Taxotere).
- •At least 3 weeks since last surgery/radiation/chemotherapy
- •ECOG Performance Status of 0, 1 or 2
排除标准
- •Active brain metastases
结局指标
主要结局
prostate cancer
prostate-specific antigen (PSA) response
次要结局
未报告次要终点
研究者
研究点 (18)
Loading locations...
相似试验
终止
2 期
Effectiveness of KOS-862 in the Treatment of Lung CancerLung CancerNCT00080509Bristol-Myers Squibb85
已完成
2 期
Eradication of Prostate Cancer Using F-989Prostate CancerNCT01987999Optimal Health Research60
进行中（未招募）
2 期
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery EmbolizationProstate CarcinomaBenign Prostatic HyperplasiaNCT04879940H. Lee Moffitt Cancer Center and Research Institute17
招募中
2 期
Low PSMA SUV Boost (LPS-Boost): Intensified 177Lu-PSMA-617 Treatment for Patients With Metastatic Castrate-Resistant Prostate Cancer With Low PSMA Expressing DiseaseStage IVB Prostate Cancer AJCC v8NCT06526299University of Washington51
进行中（未招募）
1 期
Study on patients with recurrence of prostate cancer with PET/MRRadically treated patient for prostate cancer presenting a biochemical recurrence of disease (PSA: > o = 0.2 ng/mL)MedDRA version: 21.1Level: LLTClassification code 10026389Term: Malignant neoplasm of prostateSystem Organ Class: 100000004864EUCTR2018-001036-21-ITOSPEDALE SAN RAFFAELE60